Pcsk 9 Sirna denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies PCSK9 siRNA Agents on Medical-Necessity Grounds

Cigna's medical-necessity denials for PCSK9 siRNA agents most often occur because the submitted clinical documentation does not clearly satisfy every criterion in Cigna's current coverage policy for this drug class. Common gaps include insufficient documentation of prior lipid-lowering therapy trials, an inadequate clinical narrative linking the patient's cardiovascular risk profile to the coverage criteria, or missing information about diagnosis severity. Because these agents are specialty drugs with detailed coverage criteria, even a partially complete submission can trigger a denial.

## Why This Denial Is Appealable

A medical-necessity denial is a clinical determination that can be challenged with additional documentation. Under ACA §2719 and ERISA §503, you are entitled to a full internal appeal reviewed by a qualified clinician who was not involved in the initial denial, and to independent external review if the internal appeal is unsuccessful. The external-review window is generally 4 months from the denial notice. If waiting for the standard timeline would materially worsen your condition, request expedited review at every level.

## The Appeal Process and Timeline

1. Request Cigna's specific denial rationale: they must identify which criterion was not met. This determines exactly what additional documentation to provide. 2. Gather the documentation listed below and prepare a comprehensive appeal package. 3. File Level 1 internal appeal within the deadline stated on the denial notice, typically 180 days. 4. If the internal appeal is denied: request independent external review. The external reviewer applies clinical standards independently and is not bound by Cigna's internal policy characterizations. 5. Expedited option: available at every level if standard timelines pose a clinical risk.

## Documentation to Gather

• Diagnosis confirmation: chart notes, relevant lab results, and any imaging or event records confirming the cardiovascular condition and its severity.
• Prior-treatment history: pharmacy records and chart notes documenting every lipid-lowering therapy previously tried, the duration of each trial, and the clinical outcome (inadequate LDL response documented in the chart, or documented intolerance).
• Current clinical status: most recent relevant lab values and a treating clinician's summary characterizing cardiovascular risk, referencing the applicable guideline organization's framework (such as ACC/AHA) without relying on specific numeric thresholds that should be verified against the current guideline.
• Prescriber medical-necessity letter: a detailed letter from the prescribing clinician that maps your clinical situation to each criterion in Cigna's published coverage policy for this drug class and to the FDA-approved prescribing label for the specific agent ordered.
• Cigna's current coverage policy: download the applicable clinical policy bulletin for PCSK9 inhibitors/siRNA agents. Every criterion in that document should be addressed in the appeal.

## Criteria-Mapping Structure

Build a table with one row per criterion from Cigna's clinical policy bulletin. Left column: the criterion quoted verbatim. Right column: the specific chart fact, date, lab result, or prescriber statement that satisfies it. Attach every referenced record as a labeled exhibit. This structure prevents denial-on-technicality at the internal level and gives the external reviewer a complete, navigable record.